NEW YORK (GenomeWeb News) – Epigenomics yesterday reported that its third-quarter revenues bolted up over 250 percent and its net loss declined around 10 percent year over year.

The German molecular diagnostics firm reported total revenues of €1.2 million (US$1.8 million) over the three-month period ended Sept. 30, up from €320,000 for the third quarter of 2008.

Epigenomics' net loss for the third quarter fell to €2.3 million from €2.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.